Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

This study will be conducted in two stages. Stage One is an open-label, adaptive
dose-selection, safety and efficacy trial of up to four concentrations of DE-112 ophthalmic
solution enrolling a total of 24 subjects.

Stage Two of the study is a randomized, double-masked, placebo- and active-controlled,
parallel-group, multi-center trial comparing the efficacy and safety of two concentrations of
DE-112 ophthalmic solution with placebo and timolol enrolling a total of 120 subjects.

Inclusion Criteria:

- Provide signed, written informed consent

- 18 yeas of age and older

- Diagnosed with primary open-angle glaucoma or ocular hypertension

- Female subject of childbearing potential must utilize reliable contraceptive
throughout the study and have a negative urine pregnancy test prior to enrollment into
this study

- Meet specific Visit 2, Day 0 (Baseline)criteria at baseline

Exclusion Criteria:

- Females who are pregnant, nursing or planning a pregnancy

- Presence of any abnormality or significant illness that could be expected to interfere
with the study.